PT715849E - Metodo de reducao dos efeitos induzidos pela endotoxina - Google Patents

Metodo de reducao dos efeitos induzidos pela endotoxina Download PDF

Info

Publication number
PT715849E
PT715849E PT95118986T PT95118986T PT715849E PT 715849 E PT715849 E PT 715849E PT 95118986 T PT95118986 T PT 95118986T PT 95118986 T PT95118986 T PT 95118986T PT 715849 E PT715849 E PT 715849E
Authority
PT
Portugal
Prior art keywords
endotoxin
endotoxins
medicament
arginine
body weight
Prior art date
Application number
PT95118986T
Other languages
English (en)
Portuguese (pt)
Inventor
Christer Grimfors
Ellinor Lampen
Svante Lindgren
Raymond Wahlen
Goran Sandberg
Bjorn Westberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of PT715849E publication Critical patent/PT715849E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61L2103/05—

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT95118986T 1991-01-09 1992-01-03 Metodo de reducao dos efeitos induzidos pela endotoxina PT715849E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Publications (1)

Publication Number Publication Date
PT715849E true PT715849E (pt) 2002-01-30

Family

ID=20381566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95118986T PT715849E (pt) 1991-01-09 1992-01-03 Metodo de reducao dos efeitos induzidos pela endotoxina

Country Status (11)

Country Link
EP (4) EP0719550B1 (enExample)
JP (1) JP3200604B2 (enExample)
AT (2) ATE204753T1 (enExample)
AU (1) AU9152891A (enExample)
DE (2) DE69132710T2 (enExample)
DK (2) DK0566644T3 (enExample)
ES (2) ES2109338T3 (enExample)
GR (1) GR3025573T3 (enExample)
PT (1) PT715849E (enExample)
SE (1) SE468881B (enExample)
WO (1) WO1992011847A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
ES2196053T3 (es) * 1994-01-11 2003-12-16 Stichting Zofia Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
DE69827149T2 (de) * 1997-08-15 2006-03-09 Fairbanks, Carolyn Ann, Rochester Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
CA2655873C (en) 2006-07-14 2017-10-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
EP0719550A3 (enExample) 1996-07-24
WO1992011847A1 (en) 1992-07-23
DK0719550T3 (da) 2001-12-10
SE9100059D0 (sv) 1991-01-09
GR3025573T3 (en) 1998-03-31
DK0566644T3 (da) 1998-04-27
AU9152891A (en) 1992-08-17
ATE204753T1 (de) 2001-09-15
EP0719550B1 (en) 2001-08-29
EP0715849B1 (en) 2001-07-25
DE69223426T2 (de) 1998-03-12
DE69132710D1 (de) 2001-10-04
ES2163543T3 (es) 2002-02-01
EP0715849A1 (en) 1996-06-12
EP0494848A1 (en) 1992-07-15
EP0566644B1 (en) 1997-09-10
DE69132710T2 (de) 2002-04-18
EP0494848B1 (en) 1997-03-26
EP0719550A2 (en) 1996-07-03
ATE157866T1 (de) 1997-09-15
JP3200604B2 (ja) 2001-08-20
SE468881B (sv) 1993-04-05
EP0566644A1 (en) 1993-10-27
ES2109338T3 (es) 1998-01-16
SE9100059L (sv) 1992-07-10
JPH06504058A (ja) 1994-05-12
DE69223426D1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
PT715849E (pt) Metodo de reducao dos efeitos induzidos pela endotoxina
ES2852550T3 (es) Composiciones glicopeptídicas
Zeya et al. Arginine-rich proteins of polymorphonuclear leukocyte lysosomes: antimicrobial specificity and biochemical heterogeneity
CN1323724C (zh) 获得2－18f－氟－2－脱氧－d－葡萄糖(18f－fdg)溶液的方法
PT1586580E (pt) Processo para a purificação de daptomicina
NL7905220A (nl) Antitrombinepreparaat en werkwijze ter bereiding ervan.
JP2004507463A (ja) ｏ−アセチルサリチル酸と塩基性アミノ酸との安定塩
BRPI0510269B1 (pt) Composições de dalbavancina para o tratamento de infecções bacterianas
EA001758B1 (ru) Композиции для лечения респираторного дистресс-синдрома взрослых или респираторного дистресс-синдрома новорожденных, содержащие 3-(циклопропилметокси)-n-(3,5-дихлор-4-пиридинил)-4-(дифторметокси)бензамид и легочное поверхностно-активное вещество
PT89802B (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
Opolon Large-pore hemodialysis in fulminant hepatic failure
CN110650970A (zh) 抗菌肽及其药品
PT99778B (pt) Processo para preparacao de uma transferrina humana pasteurizada e isenta de ferro
CZ302750B6 (cs) Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
GB2037161A (en) Preparations containing amino acids
JP2025533237A (ja) 液体ダルババンシン組成物
JP2025533238A (ja) 液体ダルババンシン組成物
BR112015014391B1 (pt) compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos
CN109875963B (zh) 一种头孢曲松钠注射液及其制备方法
CN1965829A (zh) 帕洛诺司琼注射液及其制备方法
CN1823775A (zh) 一种稳定的帕洛诺司琼注射液及其制备方法
US20060148895A1 (en) New composition use and method
SU728861A1 (ru) Лекарственное средство "полиамин
Barbi et al. Concentrations of free amino acids in plasma and brain in experimental coma due to flunitrazepan in guinea pigs
CANGIANO et al. Plasma aminoacid levels across the brain in patients with respiratory failure